Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Hodgkin’s Lymphoma Treatment Market "Set to Quadruple to $1.4 Billion by 2024"
January 19, 2016.
The Hodgkin’s lymphoma treatment market is set to increase more than fourfold from $316 million in 2014 to $1.4 billion by 2024, according to research and consulting firm GlobalData.
The company’s latest report states that the growth will be attributable to label extensions into earlier lines of treatment for Seattle Genetics’ Adcetris - which currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period - and the launch of new therapies for relapse or refractory (R/R) Hodgkin’s lymphoma.
OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) – Global Drug Forecast and Market Analysis to 2024
Recent Videos
Related Content
